Aloe-emodin shows multi-target promise in mouse periodontitis models

Aloe-emodin reduced inflammatory signaling and improved measures of alveolar bone repair in a mouse model of periodontitis, according to a study that combined computational target prediction with laboratory experiments. The researchers also found that the compound increased the proliferation, migration and osteogenic differentiation of mouse periodontal ligament stem cells and suppressed LPS-induced production of IL-1β, IL-6 and TNF-α. The findings identify aloe-emodin as an experimental candidate for regulating the inflammatory and bone-remodeling environment of periodontal disease, but they do not establish its effectiveness or safety in people.

The work, published in Frontiers in Pharmacology on October 20, 2026, began with a search for links between the compound and periodontitis. Inverse-docking and similarity-based prediction using PharmMapper, the SEA Search Server and the Herbal Ingredients’ Targets platform produced 290 non-redundant candidate aloe-emodin targets after the records were standardized against UniProt. Independently, the researchers collected 4,609 periodontitis-associated targets from GeneCards, OMIM and the Comparative Toxicogenomics Database. The overlap between the two collections contained 179 genes, including TNF, IL1B, TP53, EGFR, AKT1, ESR1, MMP9, GAPDH, GSK3B, MAPK14, STAT1 and CASP3.

The shared genes were examined with a protein-protein interaction network generated through STRING at a confidence score of at least 0.4, followed by topological analysis in Cytoscape and module detection with MCODE. Eleven proteins were prioritized as core targets: AKT1, TNF, TP53, EGFR, CASP3, GAPDH, MMP9, GSK3B, STAT1, ESR1 and SRC. The authors associated these nodes with inflammatory signaling, apoptosis, oxidative stress, extracellular-matrix degradation and tissue remodeling. Gene Ontology enrichment included responses to lipopolysaccharide and bacterial-derived molecules, reactive oxygen species metabolism, and positive regulation of protein kinase activity and the MAPK cascade. KEGG analysis implicated MAPK, PI3K–AKT, NF-κB, TNF and C-type lectin receptor signaling, together with FoxO, HIF-1 and VEGF pathways related to repair and angiogenesis. These are database-based predictions and associations rather than direct evidence that aloe-emodin binds or controls every identified protein.

To test selected effects, researchers worked with primary mouse periodontal ligament stem cells, or mPDLSCs, obtained from a commercial supplier. In a CCK-8 assay, aloe-emodin concentrations from 10 to 20 μM increased cell viability in a dose-dependent pattern without detectable cytotoxicity in the tested range. Concentrations above 20 μM were excluded from subsequent work because preliminary screening and previous evidence indicated a greater likelihood of nonspecific cellular stress at higher doses. Since 10 μM was the lowest concentration that produced a statistically significant proliferative effect, the researchers selected it for some follow-up experiments, while also testing higher concentrations in migration, differentiation and inflammation assays. This selection was an experimental choice rather than evidence that 10 μM is an appropriate or achievable clinical exposure.

In the stem-cell assays, 10 μM aloe-emodin increased colony formation during a 14-day period, accelerated closure of scratches in a 24-hour wound-healing test and raised the number of cells crossing Transwell membranes with 8-μm pores during 48 hours. Osteogenic induction produced higher alkaline phosphatase activity, more mineralized nodules and increased expression of osteogenesis-related markers. These observations indicate that aloe-emodin promoted proliferation, migration and osteogenic differentiation under the laboratory conditions used. The experiment involved cultured mouse cells, however, and did not establish that the same responses occur in human periodontal cells or within an intact human immune system.

The researchers also created an inflammatory challenge in the mPDLSCs. After four hours of serum starvation, the cells were exposed to lipopolysaccharide, or LPS, for 12 hours and then received graded aloe-emodin concentrations for another 12 hours. LPS increased both messenger RNA abundance and secretion of IL-1β, IL-6 and TNF-α. Aloe-emodin lowered all three cytokines in a concentration-dependent manner, with the greatest suppression reported for TNF-α; the article reports quantified reductions of 55% to 78% in the associated experiments. Western blot analysis showed dose-dependent increases in PI3KR1 and phosphorylated AKT, while total AKT changed little. The result is consistent with an effect on PI3K–AKT signaling, but the cell experiments did not show that this pathway alone caused either the cytokine reductions or the repair-related effects.

For the animal experiment, the team used female C57BL/6 mice aged 6 to 8 weeks and weighing 20–25 grams. Periodontitis was induced around the upper second molars by placing sterile silk ligatures and injecting LPS into the adjacent palatal gingiva every two days for 10 days. The animals were then randomized into five groups: a healthy control, an untreated periodontitis group and three aloe-emodin treatment groups, with five mice per group. The methods specify local administration of 1, 2.5 or 5 mg/kg into the periodontal pocket at four sites around each treated molar, every two days for 30 days. Following treatment, the maxillae were examined by micro-CT, bone mineral density analysis and histology, with some specimens decalcified for tissue sections and others scanned directly.

Three-dimensional micro-CT reconstructions showed alveolar crest height loss, rarefied trabeculae and architectural disruption in untreated periodontitis animals. Aloe-emodin treatment was associated with a dose-dependent improvement: trabecular continuity was restored, trabecular density increased, bone volume fraction and trabecular thickness rose, trabecular number increased and trabecular separation decreased. Bone mineral density increased in all three treated groups, with the largest increase at the highest reported dose. Histology showed that diseased animals without treatment had pronounced inflammatory infiltration, disorganized periodontal ligament, resorption of cementum and alveolar bone, and damage to the tooth–bone interface. Aloe-emodin reduced inflammatory infiltration, improved ligament organization and clarified that interface. Masson’s trichrome staining further indicated denser, more orderly collagen fibers, particularly at the highest dose.

The imaging and tissue findings indicate that local aloe-emodin mitigated structural bone loss and improved connective-tissue organization in this ligature- and LPS-induced mouse model. They do not demonstrate that the compound preserved teeth, restored periodontal function or would prevent disease in people. The model captures rapid alveolar bone loss, but it does not fully reproduce the diverse plaque-associated microbial community or the systemic comorbidities associated with human periodontitis. The study also did not directly test the proposed multi-target mechanism in human tissue, and public-database predictions can be affected by incomplete or biased annotations. Direct binding studies would be needed to confirm the computational target predictions.

There are also important limits on dosing and translation. The study does not provide a defined pharmacokinetic profile, making it difficult to relate local dosing in mice to exposure in people. The animal methods specify aloe-emodin doses of 1, 2.5 and 5 mg/kg, whereas the in vivo results describe concentrations of 0, 10, 15 and 20 μg/mL without clearly reconciling those measures. This inconsistency leaves the dose-response comparison less transparent. The report discusses possible antibiotic combinations, sustained-release hydrogels and other formulation strategies, but it did not test those ideas in the reported experiments. Quantitative proteomics, gene-editing perturbations, pharmacokinetic studies and large-animal testing were proposed as next steps. Until such work and human studies are available, the evidence supports aloe-emodin as a biologically active experimental candidate for periodontal research, not as a proven clinical therapy.

Subject of Research: Experimental assessment of aloe-emodin as a multi-target modulator of periodontal inflammation and alveolar bone repair

Article Title: Unraveling the multitarget mechanisms of aloe emodin against periodontitis: a synergy of network pharmacology and experimental validation

Article References: Zhang, Y., Ma, H., Zhang, S., Jing, D., Liang, H., Wang, Y., Li, Z., & Yan, H. (2026). Unraveling the multitarget mechanisms of aloe emodin against periodontitis: a synergy of network pharmacology and experimental validation. Frontiers in Pharmacology, 17, Article 1944429. https://doi.org/10.3389/fphar.2026.1944429

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1944429

Keywords: aloe-emodin, periodontitis, network pharmacology, periodontal ligament stem cells, alveolar bone repair, inflammation, PI3K–AKT signaling, TNF, osteogenesis, mouse model, Unraveling, multitarget